CRISPR's Zugo-cel Shows Promise in Treating Autoimmune Diseases

Overview of Zugo-cel

CRISPR Therapeutics recently provided an update on its investigational CAR-T cell therapy, zugocabtagene geleucel (zugo-cel), at the ACR Convergence 2026 event. This innovative therapy is designed to treat refractory rheumatologic autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathy (IIM).

Positive Clinical Findings

As of mid-October 2026, 21 patients have participated in the ongoing Phase 1 basket trial. Notably, data presented regarding SSc revealed significant clinical responses. After three months of treatment, 83% of SSc patients who underwent standard lymphodepletion achieved a revised Clinical Response Index in Systemic Sclerosis (rCRISS-25). Impressively, among these, two patients met the more demanding rCRISS-50 criteria, maintaining their responses well beyond the three-month mark.

Dr. Naimish Patel, Chief Medical Officer of CRISPR Therapeutics, articulated the burden that patients with autoimmune diseases bear, stating, "These patients often grapple with progressive disease and the lifelong implications of immunosuppressive treatments. The observed responses and favorable tolerability of zugo-cel reinforce our belief in its potential as a transformative treatment option for these patients."

Safety Profile and Efficacy Across Cohorts

The safety profile of zugo-cel remains promising, as no patients have reported severe adverse events. Specifically, there have been no incidents of cytokine release syndrome higher than Grade 2, nor cases of immune effector cell-associated neurotoxicity syndrome or other severe complications. As the study continues, the possibility of increasing the dosage is being explored, with encouraging signs of higher CAR-T cell expansion at 200 million CAR+ cells compared to the initial 100 million dosage.

Results from IIM patients are equally significant, with all nine individuals achieving moderate to major Total Improvement Scores (TIS). This group includes patients diagnosed with conditions such as immune-mediated necrotizing myopathy and dermatomyositis, reflecting the therapy's broad applicability.

Preliminary outcomes in the SLE cohort also demonstrate promise, where two out of three evaluable patients have sustained drug-free remission for at least nine months, with one patient maintaining it for over a year.

About Zugocabtagene Geleucel (Zugo-cel)

As a product of advanced gene-editing technology, zugo-cel utilizes CRISPR/Cas9 for generating allogeneic chimeric antigen receptor T cells that specifically target CD19. This off-the-shelf therapy showcases significant innovation in immunotherapy, designed for quicker availability without requiring patient-specific HLA matching.

In addition to its rheumatology applications, zugo-cel is being investigated across various trials for conditions like immune thrombocytopenic purpura and different autoimmune neurological disorders. Its potential extends into the realm of immuno-oncology, targeting B-cell malignancies.

Conclusion

With these encouraging results, CRISPR Therapeutics continues to advance zugo-cel. Future developments may offer new avenues for patients suffering from challenging autoimmune diseases, enhancing their quality of life and treatment outcomes.